NASDAQ:PTCT PTC Therapeutics Q3 2026 Earnings Report $63.70 +0.05 (+0.08%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$63.55 -0.15 (-0.24%) As of 08:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PTC Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.29Beat/MissN/AOne Year Ago EPSN/APTC Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$303.94 millionBeat/MissN/AYoY Revenue GrowthN/APTC Therapeutics Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile PTC Therapeutics Earnings HeadlinesPTC Therapeutics (NASDAQ:PTCT) Director Glenn Md Phd Steele, Jr. Sells 12,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 25, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene TherapySeptember 22, 2026 | finanznachrichten.dePTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4September 22, 2026 | rttnews.comPTC Completes Acquisition of ST-920 Fabry Disease Gene TherapySeptember 21, 2026 | prnewswire.comSee More PTC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email. Email Address About PTC TherapeuticsPTC Therapeutics (NASDAQ:PTCT) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy. The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients. PTC has also developed Translarna (ataluren) for certain genetic disorders involving nonsense mutations and is advancing candidates such as sepiapterin for phenylketonuria and vatiquinone for mitochondrial diseases. PTC serves patients and healthcare providers through commercial operations in the United States and international markets, including Europe and other regions. The company was founded in 1998 and is headquartered in Warren, New Jersey. Matthew B. Klein serves as PTC Therapeutics’ chief executive officer.View PTC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
